Brochure
11 Nov 2023

Mabion - Your Biologics CDMO

PDF 2.2 MB

A presentation including a demonstration of Mabion's capabilities as a biologics CDMO.

Content provided by our supplier

Mabion SA

  • PL
  • 2023
    On CPHI since
  • 3
    Certificates
  • 250 - 499
    Employees
Company types
CMO/CDMO
Primary activities
Analytical Services
Biopharmaceutical
Clinical Research
Contract Manufacturer
Contract Research Organisation
End-product distributor (Wholesale)
Intermediates Manufacturer

Other Content from Mabion SA (1)

  • News Mabion signs contract to purchase new bioreactors, diversifies technology, and opens to new customers

    On July 11th, 2023, Mabion concluded an agreement with Global Life Sciences Solutions Polands Sp. z o.o., a Cytiva group company for the purchase of a set of Xcellerex XDR bioreactors with conventional mixing technology. The contract is valued at EUR 3.2 million.The vendor will manufacture and install a set of bioreactors in Mabion's facility in Konstantynów Łódzki, Poland, delivery of which is scheduled for Q3 2023, followed by installation, commissioning, qualification testing and acceptance of the equipment. The Xcellerex XDR bioreactor suite is based on technology using a conventional mixing system, as opposed to Mabion's current orbital shaking technology, which will allow the Company to achieve technological diversification, as outlined in the 2023-2027 Strategy in earlier this year.